AstraZeneca Nabs CinCor’s Hypertension Asset In $1.3bn Acquisition
Potential Combination With Farxiga
Executive Summary
The UK major is acquiring CinCor in a deal that could be worth up to $1.8bn, in return getting hold of its Phase II hypertension candidate, baxdrostat, which offers combination potential with Farxiga.
You may also be interested in...
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.
The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest
Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.
BI/Lilly’s Jardiance To Face Off With AstraZeneca’s Farxiga In CKD After EU Nod
The SGLT2 inhibitor has won European approval for the treatment of chronic kidney disease and while rival AstraZeneca’s Farxiga has had a two-year head start in the space, Boehringer and Lilly could come out on top given Jardiance’s stronger sales records to date.